Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion

Ophthalmologica

Volumn 225, Issue 3, 2011, Pages 150-154

  Lim, Ji Won ^a  

^a Hallym University   (South Korea)

Author keywords

Branch retinal vein occlusion; Cytokines; Intravitreal bevacizumab; Site of occlusion

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RECURRENT DISEASE; RETINA MACULA EDEMA; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; CYTOKINES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78649763817     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322364     Document Type: Article

References (21)

1. McIntosh R, Mohamed Q, Saw S, Wong T: Interventions for branch retinal vein occlusion. Ophthalmology 2006; 114: 835-854.
2. Shahid H, Hossain P, Amoaku WM: The management of retinal vein occlusion: Is interventional ophthalmology the way forward? Br J Ophthalmol 2006; 90: 627-639.
3. Rehak J, Rehak M: Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-131. (Pubitemid 351302200)
4. Parodi MB, Saviano S, Ravalico G: Grid laser treatment in macular branch retinal vein occlusion. Graefe's Arch Clin Exp Ophthlamol 1999; 237: 1024-1027. (Pubitemid 30021293)
5. Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, Ota I, Kensaku M, Terasaki H: Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: Results after 12 months and multiple regression analysis. Retina 2009; 29: 1242-1248.
6. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S: Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1635-1641.
7. Figueroa MS, Contreras I, Noval S, Arruabarrena C: Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 2010; 94: 1052-1056.
8. Parodi MB, Saviano S, Bergamini L, Ravalico G: Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc Ophthalmol 1999; 97: 427-431.
9. Orth DH, Patz A: Retinal branch vein occlusion. Surv Ophthalmol 1978; 22: 357-376. (Pubitemid 8384633)
10. Finkelstein D: Ischemic macular edema: Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992; 110: 1427-1434.
11. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ: Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1241-1247.
12. Joffe L, Goldberg RE, Magargal LE, Annesley WH: Macular branch vein occlusion. Ophthalmology 1980; 87: 91-98. (Pubitemid 10113532)
13. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140: 256-261.
14. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK: Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008; 22: 42-48.
15. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK: Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006; 244: 309-315.
16. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt- Erfurth U: Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009; 50: 1025-1032.
17. Abegg M, Tappeiner C, Wolf-Schnurrbusch U, Barthelmes D, Wolf S, Fleischhauer J: Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008; 8: 18.
18. Schober A, Zernecke A: Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730-737. (Pubitemid 46779958)
19. Hoshino M, Takahashi M, Aoike N: Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001; 107: 295-301. (Pubitemid 32173907)
20. Yoshida M, Tanihara H, Yoshimura N: Platelet- derived growth factor gene expression in cultured human retinal pigment epithelial cells. Biochem Biophys Res Commun 1992; 189: 66-71. (Pubitemid 23030009)
21. Heldin CH, Ostman A, Rönnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998; 1378:F79-F113. (Pubitemid 28381127)